Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aegerion Pharmaceuticals Appoints Diane L. Tribble, Ph.D., M.M.Sc., as Chief Scientific Officer
Lipids Expert Adds Extensive Experience in Cholesterol-Lowering Drug Development
View HTML
Toggle Summary QLT Receives Positive Opinions for Orphan Drug Designation by the European Medicines Agency for QLT091001 to Treat Two Hereditary Blindness Diseases
QLT Receives Positive Opinions for Orphan Drug Designation by the European Medicines Agency for QLT091001 to Treat Two Hereditary Blindness Diseases   VANCOUVER, British Columbia, Feb 10, 2011 (GlobeNewswire via COMTEX) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced
View HTML
Toggle Summary QLT Announces Phase II Clinical Trial Results for the Olopatadine Punctal Plug Delivery System (O-PPDS)
QLT Announces Phase II Clinical Trial Results for the Olopatadine Punctal Plug Delivery System (O-PPDS)   VANCOUVER, British Columbia, Feb 9, 2011 (GlobeNewswire via COMTEX) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced results from a Phase II proof-of-concept
View HTML
Toggle Summary Aegerion Pharmaceuticals to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
BRIDGEWATER, N.J., Feb. 8, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the Leerink
View HTML
Toggle Summary Aegerion Pharmaceuticals Appoints Martha J. Carter as Chief Regulatory Officer
Pharmaceutical Industry Veteran Adds Extensive Regulatory Expertise
View HTML
Toggle Summary Aegerion Pharmaceuticals Unveils New Corporate Identity and Website
Company Opens New Corporate Headquarters in Cambridge, MA
View HTML
Toggle Summary Aegerion Pharmaceuticals to Present at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
BRIDGEWATER, N.J., Dec. 1, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the 5 th Annual
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Third-Quarter 2010 Financial Results
BRIDGEWATER, N.J., Nov. 30, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights
View HTML
Toggle Summary Aegerion Pharmaceuticals to Announce Third-Quarter 2010 Financial Results on Tuesday, November 30
BRIDGEWATER, N.J., Nov. 23, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced that the Company will host a conference call and
View HTML
Toggle Summary Aegerion Pharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
BRIDGEWATER, N.J., Nov. 5, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the Lazard
View HTML